News Breaks |
|
|
| September 17, 2012 |
| 07:31 EDT |  | LIFE, BMY | Life Technologies to partner with Bristol-Myers for diagnostics development
Life Technologies (LIFE) announced that the company has entered into a Master Development Agreement with Bristol-Myers (BMY) for current and future companion diagnostics projects. The current agreement constitutes the second collaboration between the two companies and represents another step in Life Technologies' strategy to develop its diagnostic business through internal development, partnerships and select acquisitions. The agreement covers an initial project for oncology and provides for a long-term partnership across a potentially broad range of Life instrument platforms and a wide range of therapeutic areas. |
|
|
News For LIFE;BMY From The Last 14 Days Check below for free stories on LIFE;BMY the last two weeks. |
|
|
| May 22, 2013 |
| 16:00 EDT |  | BMY | Options Update; May 22, 2013
 Subscribe for More Information |
|
| 10:33 EDT | | BMY | Bristol-Myers jumps after Citi ups rating on cancer potential
Subscribe for More Information |
|
| 10:16 EDT |  | BMY | Bristol-Myers spikes higher following upgrade, levels to watch
Subscribe for More Information |
|
| 10:00 EDT |  | BMY | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 06:05 EDT | | BMY | Bristol-Myers upgraded to Buy from Neutral at Citigroup
Subscribe for More Information |
|
| May 21, 2013 |
| 20:03 EDT |  | LIFE | Roche, Sigma-Aldrich teamed for Life bid, Reuters says
Subscribe for More Information |
|
| 10:00 EDT |  | LIFE | On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Acquity Group (AQ) downgraded to Neutral from Buy at Roth Capital... Beazer Homes (BZH) downgraded to Neutral from Buy at Sterne Agee... CME Group (CME) downgraded to Neutral from Outperform at Macquarie... Carnival (CCL) downgraded to Neutral from Buy at UBS... Coach (COH) downgraded to Equal Weight from Overweight at Morgan Stanley... Deutsche Bank (DB) downgraded to Neutral from Overweight at JPMorgan... First Republic Bank (FRC) downgraded to Hold from Buy at Jefferies... Franklin Resources (BEN) downgraded to Neutral from Outperform at Macquarie... Life Technologies (LIFE) downgraded to Underperform from Outperform at CLSA... Oil States (OIS) downgraded to Neutral from Buy at Sterne Agee... Raymond James (RJF) downgraded to Market Perform from Outperform at Wells Fargo... VF Corp. (VFC) downgraded to Market Perform from Outperform at Wells Fargo... WellCare (WCG) downgraded to Neutral from Buy at Goldman... Huaneng Power (HNP) downgraded to Neutral from Buy at Citigroup... Comerica (CMA) downgraded to Neutral from Buy at DA Davidson... Beazer Homes (BZH) downgraded at Sterne Agee... Oil States (OIS) downgraded at Sterne Agee... eHealth (EHTH) downgraded to Neutral from Buy at Lazard Capital... Carnival (CCL) downgraded to Market Perform from Outperform at Wells Fargo... Warner Chilcott (WCRX) downgraded to Neutral from Positive at Susquehanna. |
|
| 07:34 EDT |  | BMY | UBS to host a conference
Subscribe for More Information |
|
| 07:24 EDT | | BMY | Global Health Care to host a conference
Subscribe for More Information |
|
| 06:26 EDT | | LIFE | Life Technologies downgraded to Underperform from Outperform at CLSA
CLSA downgraded Life Technologies citing the takeout bid by Thermo Fisher. Price target is $76. |
| |
| May 20, 2013 |
| 10:03 EDT | | BMY | Shire advances after report renews takeover speculation
Subscribe for More Information |
|
| 06:30 EDT |  | BMY | Leerink estimates Shire takeout value at least $110 per share
Leerink says a takeover price for Shire (SHPG) would need to be at least $110 per share in order to get the company's board to consider a sale. The firm notes a Daily Mail report last night said Bristol-Myers (BMY) has engaged advisors to study an acquisition of Shire and that Shire's CEO has contacted bankers to consider anti-takeover measures. Leerink believes a Bristol-Myers takeover of Shire would make sense and keeps an Outperform rating on Shire. |
|
| 06:25 EDT | | BMY | Shire may return cash to thwart takeover, Daily Mail reports
Subscribe for More Information |
|
| May 17, 2013 |
| 13:21 EDT | | BMY | Options with increasing implied volatility: CPRT BMY GDI HNZ
Subscribe for More Information |
|
| May 16, 2013 |
| 16:32 EDT | | BMY | Bristol-Myers announces intention to voluntarily delist preferred stock
Subscribe for More Information |
|
| 13:20 EDT | | BMY | Follow-up: Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Bristol-Myers citing the company's multi-billion dollar immuno-oncology prospects. The firm says there were additional responses reported in the press briefing with combination nivolumab and Yervoy. Leerink has a $51 price target for shares. |
|
| 13:14 EDT | | BMY | Bristol-Myers upgraded to Outperform from Market Perform at Leerink
Subscribe for More Information |
|
| 08:55 EDT | | BMY | BofA/Merrill's pharmaceuticals analysts hold analyst/industry conference call
Subscribe for More Information |
|
| 08:38 EDT | | BMY | Bristol-Myers shares likely to give back recent gains, says Leerink
Leerink expects shares of Bristol-Myers to give back recent gains after ASCO published abstracts last night. The firm found the abstracts as in-line with, but not above, its expectations for nivolumab alone or immuno-oncology combination therapy and keeps a Market Perform rating on Bristol-Myers. |
|
| 05:52 EDT | | BMY | Stocks with implied volatility movement; BMY SLV
Subscribe for More Information |
| |
|
|
|
|
